Recently, the HER2 targeting monoclonal antibody trastuzumab was approved for treatment of HER2-positive metastatic gastric and gastroesophageal junction cancer based on results of the Trastuzumab with chemotherapy in HER2-positive advanced Gastric Cancer (ToGA) clinical trial [6]. This evidence concerns the gene ERBB2 and gastric cancer.